ImmunityBio, Inc. (IBRX) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は San Diego, CA, アメリカ. 現CEOは Richard Gerald Adcock.
IBRX を有する IPO日 2015-07-28, 671 名の正社員, に上場 NASDAQ Global Select, 時価総額 $7.81B.
ImmunityBio, Inc. is a clinical-stage biotechnology company headquartered in San Diego that develops immunotherapies and vaccines for cancer and infectious diseases. The company's pipeline includes advanced immunotherapy and cell therapy platforms, featuring antibody-cytokine fusion proteins, synthetic immunomodulators, natural killer cells, and T cell therapies, with multiple candidates in Phase II and III clinical trials for liquid and solid tumors such as bladder, pancreatic, and lung cancers, as well as viral pathogens including SARS-CoV-2 and HIV. ImmunityBio has established strategic partnerships with leading research institutions including the National Cancer Institute and collaboration or licensing agreements with multiple biotechnology and healthcare organizations to advance its therapeutic pipeline.
